Noémie is a student at FMS Muttenz. She completed a two-week internship at HEMEX focusing on graphic design and has accompanied our team during daily activities. Here’s a summary of her experience written by Noémie herself.
Liestal, Switzerland, September 2023 – HEMEX, a bench-to-market clinical Contract Research Organization (CRO) announces the incorporation of a new subsidiary in Leuven, Belgium. This strategic expansion marks another significant milestone in the company’s growth and commitment to serving its European customers.
Schlieren, Switzerland, August 24th 2023 – hemotune AG, a pioneering MedTech startup revolutionizing blood purification with cutting-edge nanotechnology, proudly announces its attainment of ISO 13485 certification. The certification covers design and development, production, distribution, and service of medical devices for blood purification including coated colloidal nanoparticles and marks a significant milestone towards delivering its innovative blood purification technology to patients.
Schlieren (Switzerland), 23rd March 2023 – hemotune AG, the Schlieren-based MedTech company known for its magnetic blood purification platform announces a joint feasibility project with the global pharmaceutical company AstraZeneca.
Callum is a student at Gymnasium Liestal. He applied for a one-week internship at HEMEX and has spent the last week accompanying the team during our daily activities. Here’s a sum-up of his week written by Callum himself.
Last week we were honored to organize a Social Media workshop with the startup macu4 where we had a valuable conversation about how beneficial is to define e.g., your strategy, brand awareness, or target group to grow and accelerate your business.
Eating healthier, regular exercise, or reading more books – many people use the New Year to tackle new projects or follow through on old plans. What’s on your list of New Year’s resolutions for 2022?
Market tracking is not only exciting but has recently become a requirement under the Medical Device regulations (MDR) of the EU. Join us in learning what steps are necessary to complete the post-market clinical follow-up!
We’re delighted to announce that our portfolio startup Resistell AG has completed the pilot phase of its clinical Performance Evaluation
Study (PES) with 100% accuracy and at least 7 hours shorter time-to-result (TTR) compared to gold standard methods.